STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

DYN Schedule 13G filing by T. Rowe Price Investment Management

T. Rowe Price Investment Management reported beneficial ownership of 17.5M shares, representing 12% of DYNE THERAPEUTICS INC in this filing.

FiledJan 8, 2026
Ownership dateDec 31, 2025
Reported shares17.5M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 17.5M
Shared voting power 17.5M
Sole dispositive power 17.5M
Shared dispositive power 17.5M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$18.26as of Jan 8, 2026
Latest tracked price$25.97as of Aug 4, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
T. Rowe Price Investment Management
CIK
CIK0001897612
Accession
0001897612-26-000009
Form
Schedule 13G
Open SEC filing View DYN ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →